Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 3;11(9):e007552. doi: 10.1136/jitc-2023-007552

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Overall survival and progression-free survival (ITT population). Kaplan-Meier probability curves of OS (A, C) and PFS (B, D) in relation to treatment regimen for the pooled population (n=31) and chemotherapy-naïve subgroup (n=17). Censored values (+) indicate the last follow-up time for patients who were alive after study completion. P values were obtained by log-rank tests. Control is pemetrexed (500 mg/m²) in combination with cisplatin (75 mg/m²) or carboplatin (AUC 5). ONCOS-102 is ONCOS-102 (3×10¹¹ virus particles in 2.5 mL) with pemetrexed (500 mg/m²) in combination with cisplatin (75 mg/m²) or carboplatin (AUC 5). ITT, intention to treat; NA, not assessable; PFS, progression-free survival; OS, overall survival.